The incidence of second malignancies following hematopoietic SCT (HSCT) is low, B5%. 1 The majority of these are hematological, with epithelial malignancies occurring at an incidence of 1-2% at 10-years post transplant, and increasing over time. 1 Allogeneic transplant recipients have a 2-6 times higher risk of developing solid tumors when compared with the general population. [1] [2] [3] Here, we present the case of a 34-year-old male patient who was diagnosed with a new carcinoma very soon after allogeneic HSCT. He had no significant past medical history when he presented with appendicitis. Computerized tomography (CT) scan also showed retroperitoneal, cervical, supraclavicular, mediastinal and axillary lymphadenopathy. Following appendectomy, an excisional biopsy of the axillary lymph node demonstrated peripheral T-cell lymphoma (PTCL) not otherwise specified (Figure 1a) . Cerebrospinal fluid and BM biopsy confirmed lymphoma involvement. Treatment comprised induction chemotherapy with dose-adjusted etoposide, vincristine, doxorubicin, CY and prednisone with rituximab (for prevention of PTLD) plus siplizumab, a monoclonal anti-CD2 Ab (DA-EPOCH-RS) and intrathecal MTX. After six cycles CR was confirmed by CT/PET (positron emission tomography), marrow biopsy and CSF evaluations. biopsy on day 28 post transplant showed no evidence of lymphoma. On day 141, the patient was diagnosed with a new erosive lesion in the right second rib, which coalesced with a soft tissue mass in the right lung apex (Figure 2a ). Fine needle aspirate cytology of the rib noted atypical large cells with similar morphology to the original lymphoma; molecular testing confirmed the identical clonal TCR rearrangement (not shown). The patient received re-induction with EPOCH-fludarabine followed by a DLI. The treatment was complicated by grade 3 acute GVHD of the liver requiring immunosuppression with tacrolimus, mycophenolate mofetil and prednisone. A new skin lesion appeared on post-transplant day 186 on the right upper back. Histopathology of the biopsy showed a sparse mononuclear infiltrate, which did not stain for B-cell, T-cell or macrophage markers, and was considered atypical but not diagnostic of lymphoma (Figure 1c) . Soon after the patient developed respiratory symptoms with cough, purulent sputum and lung infiltrates on CT scan (Figure 2b ). Stains and cultures showed a mold (Aspergillus) and Streptococcus pneumonia and anti-fungal and anti-bacterial therapies were initiated. Follow-up CT noted resolution of infiltrates in certain areas of the lung but progression in others (Figure 2b ), leading to worsening respiratory failure, endotracheal intubation and mechanical ventilation. The lung infiltrate was biopsied on day 234 post transplant, (Figure 2b ) and histopathology showed poorly differentiated carcinoma, unknown primary (CUP), (Figure 1d ). Retrospective evaluation of the skin and rib biopsies demonstrated similar keratin-positive staining patterns, confirming the presence of both PTCL and CUP in the rib and skin lesions (Figures 1b and c) . The confounding factor in the original histopathology analyses was the degree of anaplastic features of the tumor. As molecular studies supported the recurrence of lymphoma no further immunohistochemistry was performed at the time. The patient was treated with five daily doses of singleagent cisplatin (total dose 100 mg/m 2 ), due to the constraints of hepatic GVHD and severe thrombocytopenia. There was no clinical response and the patient died soon, autopsy permission was not granted.
Previous literature attributes second cancers after HSCT to conditioning radiation therapy, chronic GVHD, immunosuppressive treatments or to underlying disease, for example Fanconi's anemia. [1] [2] [3] [4] Epithelial secondary malignancies typically occur many years after transplant. Reported carcinomas include glioblastoma, squamous cell carcinoma (oral-cavity, skin, vulva), melanoma, basal cell carcinoma, ovarian, gastric and renal carcinomas as well as adenocarcinoma of the lung, liver and rectum. [1] [2] [3] [4] [5] [6] New epithelial malignancies within o6 months are, however, exceptionally rare. Upon our review of the literature only eight such cases were identified: lung (2), stomach (2), renal (1), ovarian (1) and colon (2). [4] [5] [6] [7] [8] Second cancers after transplant are usually recipientderived, but there are cases of donor origin. A recent review of donor-derived second malignancies after HSCT reported 11 such cases published, these included cases of invasive breast adenocarcinoma (1), oral squamous cell carcinoma (7), lung squamous cell carcinoma (1), Kaposi's sarcoma (1) and glioblastoma multiforme (1) occurring at an average of 7.9 (range 1-22) years after HSCT. 8 In the current patient, donor origin was excluded by karyotype studies (see Figure 1d ), pointing to a preexisting (second) or 'de-novo' (secondary) tumor of host origin. [1] [2] [3] [4] 7 The timing of epithelial malignancy occurring so early after HSCT as in this case, is very atypical. Radiation therapy was not used for conditioning and cases of second malignancy have not been reported following EPOCH chemotherapy. This unusually early presentation of an aggressive new carcinoma could be related to high-intensity immunosuppression (by anti-CD2 Ab, transplant conditioning and/or GVHD prophylaxis), leading to activation of the immunologically 'restrained' cancer cells and acceleration of proliferation and growth. Such instances of early new cancer presentations after HSCT may have implications for studying mechanisms of tumorigenesis and cancer immunosurveillance. 9, 10 In summary, although early second cancers post allogeneic HSCT are very rare they should be considered in the differential diagnosis of post-transplant hematologic malignancy relapse in a patient with an unusual clinical presentation. The possibility of very early cancers and the broader significance of this phenomenon should also mandate adherence to details in reporting cases with such clinical presentations.
